MENU
+Compare
ZLAB
Stock ticker: NASDAQ
AS OF
Apr 3, 03:12 PM (EDT)
Price
$36.82
Change
+$0.39 (+1.07%)
Capitalization
3.97B

ZLAB Zai Lab Limited Forecast, Technical & Fundamental Analysis

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases... Show more

Industry: #Biotechnology
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ZLAB with price predictions
Apr 02, 2025

ZLAB in downward trend: price expected to drop as it breaks its higher Bollinger Band on March 14, 2025

ZLAB broke above its upper Bollinger Band on March 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In of the 35 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ZLAB moved out of overbought territory on March 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ZLAB as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ZLAB turned negative on March 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZLAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where ZLAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 181 cases where ZLAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.690) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (9.033) is also within normal values, averaging (252.036).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ZLAB is expected to report earnings to rise 580.50% to -54 cents per share on May 13

Zai Lab Limited ZLAB Stock Earnings Reports
Q1'25
Est.
$-0.54
Q4'24
Beat
by $0.65
Q3'24
Beat
by $0.73
Q2'24
Missed
by $0.11
Q1'24
Beat
by $0.88
The last earnings report on February 27 showed earnings per share of -7 cents, beating the estimate of -73 cents. With 319.10K shares outstanding, the current market capitalization sits at 3.97B.
A.I. Advisor
published General Information

General Information

a service for cancer & autoimmune treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4560 Jinke Road
Phone
+86 2161632588
Employees
2175
Web
https://www.zailaboratory.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BFOR70.620.86
+1.23%
Barron's 400 ETF
EWA23.890.18
+0.76%
iShares MSCI Australia ETF
SAGP30.380.20
+0.66%
Strategas Global Policy Opp ETF
SZK11.800.01
+0.10%
ProShares UltraShort Consumer Staples
CEMB45.01N/A
-0.01%
iShares JP Morgan EM Corporate Bond ETF

ZLAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
-2.31%
ONC - ZLAB
42%
Loosely correlated
+1.38%
MDGL - ZLAB
38%
Loosely correlated
+3.28%
GOSS - ZLAB
33%
Loosely correlated
-1.59%
AMRN - ZLAB
33%
Loosely correlated
-2.26%
ABOS - ZLAB
33%
Poorly correlated
+0.47%
More